SCHEMBL3061671

SCHEMBL3061671

COC(=O)C1c2ccc(OCc3cc(OC)cc(OC)c3F)cc2CCN1C(=O)OCC(C)C

nearest known ligand 0.45

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
GHSR Q92847 14/20 0.45
POLB P06746 1/20 0.42
TP53 P04637 1/20 0.40
LMNA P02545 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3077104 0.90 GHSR (0.48) GHSRTP53
SCHEMBL3069115 0.90 GHSR (0.47) GHSRPOLB
SCHEMBL3061670 0.87 GHSR (0.51) GHSR
SCHEMBL3080155 0.87 GHSR (0.46) GHSRPOLBTP53
SCHEMBL3074927 0.87 GHSR (0.48) GHSR
SCHEMBL3069134 0.87 GHSR (0.54) GHSR
SCHEMBL3071279 0.87 GHSR (0.53) GHSR
SCHEMBL3061545 0.86 GHSR (0.48) GHSR
SCHEMBL3067390 0.86 GHSR (0.52) GHSR
SCHEMBL3075934 0.86 GHSR (0.55) GHSR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1951675-B1 TETRAHYDROISOQUINOLINE AS LXR MODULATORS BRISTOL MYERS SQUIBB CO (US) 2013-03-20 EP disclosed
US-7790745-B2 Tetrahydroisoquinoline LXR Modulators BRISTOL-MYERS SQUIBB COMPANY (US) 2010-09-07 US disclosed
US-20070093523-A1 Tetrahydroisoquinoline LXR modulators BRISTOL-MYERS SQUIBB COMPANY 2007-04-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070093523-A1 Tetrahydroisoquinoline LXR modulators NR1H2, NR1H3, NR1I2 GHSR 351/4885POLB 2287/4885TP53 3851/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.